Clinical trials in Saronno – page 96

2 862 clinical trials in Saronno, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Saronno at a glance

2 862

clinical trials

Research sites1

Quick filters

2 862 trials in Saronno

Open in trial search

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Angelman's syndrome

Not yet recruiting

Study of the safety and efficacy of intrathecal rugonersen sodium in children and adults with Angelman syndrome

InvestigationalNo placebo

Study of the safety and efficacy of intrathecal rugonersen sodium in children and adults with Angelman syndrome

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years
Sponsor:Ohb Pediatrics Limited

Contact Research Centre

Chronic obstructive pulmonary disease

Not yet recruiting

Study of Tozorakimab to Reduce Lung Inflammation and Promote Healing in Patients with COPD

Investigational

Study of Tozorakimab to Reduce Lung Inflammation and Promote Healing in Patients with COPD

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Tozorakimab
Sponsor:University Of Leicester

Contact Research Centre

Colorectal adenocarcinoma

Not yet recruiting

A Phase 2 Study of VS-7375 Alone or with Drug Combination in Patients with Metastatic KRAS G12D‑Mutated Colorectal Cancer

Registered drugNo placebo

A Phase 2 Study of VS-7375 Alone or with Drug Combination in Patients with Metastatic KRAS G12D‑Mutated Colorectal Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Verastem Inc.

Contact Research Centre

C3 glomerulopathy

Not yet recruiting

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegcetacoplan
Sponsor:Swedish Orphan Biovitrum AB (publ)

Contact Research Centre

Chronic lymphocytic leukaemia+2

Not yet recruiting

Comparison of rocbrutinib versus pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo

Comparison of rocbrutinib versus pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Pirtobrutinib
Sponsor:Newave Pharmaceutical Inc.

Contact Research Centre

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Infection prophylaxis

Not yet recruiting

Study of human normal immunoglobulin to prevent major infections in patients with hypogammaglobulinemia and autoimmune/rheumatic disease on B‑cell depletion therapy

Registered drug

Study of human normal immunoglobulin to prevent major infections in patients with hypogammaglobulinemia and autoimmune/rheumatic disease on B‑cell depletion therapy

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Contact Research Centre

Prostate cancer

Not yet recruiting

Evaluation of [99mTc]PSMA I&S PET‑Guided Navigation with Electromagnetic Tracking in miN1 Prostate Cancer Patients Undergoing Radio‑Guided Surgery

InvestigationalNo placebo

Evaluation of [99mTc]PSMA I&S PET‑Guided Navigation with Electromagnetic Tracking in miN1 Prostate Cancer Patients Undergoing Radio‑Guided Surgery

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:[99MTC]PSMA I&S
Sponsor:Ospedale San Raffaele S.r.l.

Contact Research Centre

Effect of febuxostat on insulin resistance in adults with cardiometabolic disease and mild chronic hyperuricemia: a randomized, double‑blind, placebo‑controlled trial

Not yet recruiting

Registered drug

Effect of febuxostat on insulin resistance in adults with cardiometabolic disease and mild chronic hyperuricemia: a randomized, double‑blind, placebo‑controlled trial

Registered drug

Italy

Participants:18–64 years · 65+ years
Sponsor:Societa Italiana Dell’ipertensione Arteriosa Lega Italiana Contro l’Ipertensione Arteriosa

Contact Research Centre

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Human Normal Immunoglobulin
Sponsor:CSL Behring LLC

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Saronno

What the registry says about research in the country

01 Respiratory Oncology

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, including studies evaluating novel therapeutic approaches for patients with specific genetic mutations.

MET deregulation therapy assessment
Second-line combination treatments
EGFR mutation targeting

Research emphasizes personalized treatment strategies for advanced and metastatic disease states.

02 Women's Oncology

Comprehensive studies addressing breast cancer and gynecological malignancies, with focus on treatment timing and maintenance therapies.

Endocrine-responsive breast cancer treatment
Ovarian cancer maintenance therapy
BRCA wild-type cancer management

Investigations aim to optimize treatment sequences and improve patient outcomes.

03 Specialized Oncology & Cardiology

Innovative research in renal cell carcinoma treatment and cardiac conditions, particularly focusing on novel therapeutic approaches.

Metastatic renal cancer therapy
Atrial fibrillation management
Targeted combination therapies

Studies evaluate both oncological interventions and cardiovascular treatments for high-risk patients.

Back to Italy All countries